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Abstract
Introduction: Prediction of optimal cytoreduction in patients with advanced epithelial ovarian caner
preoperatively.
Methods: Patients with advanced epithelial ovarian cancer who underwent surgery for the first time from Jan. to
June 2008 at gynecologic oncology ward of TUMS (Tehran University of Medical Sciences) were eligible for this
study. The possibility of predicting primary optimal cytoreduction considering multiple variables was evaluated.
Variables were peritoneal carcinomatosis, serum CA125, ascites, pleural effusion, physical status and imaging
findings.
Univariate comparisons of patients underwent suboptimal cytoreduction carried out using Fisher’s exact test for
each of the potential predictors. The wilcoxon rank sum test was used to compare variables between patients with
optimal versus suboptimal cytoreduction.
Results: 41 patients met study inclusion criteria. Statistically significant association was noted between peritoneal
carcinomatosis and suboptimal cytoreduction. There were no statistically significant differences between physical
status, pleural effusion, imaging findings, serum CA125 and ascites of individuals with optimal cytoreduction
compared to those with suboptimal cytoreduction.
Conclusions: Because of small populations in our study the results are not reproducible in alternate populations.
Only the patient who is most unlikely to undergo optimal cytoreduction should be offered neoadjuvant
chemotherapy, unless her medical condition renders her unsuitable for primary surgery.
Introduction
Ovarian cancer is the leading cause of morbidity and
mortality among the gynecologic cancers [1]. Epithelial
ovarian cancers consist 90% of all ovarian cancers [2].
Stage 3 and 4 (as defined by the staging classification of
the International Federation of Gynecology and Obste-
trics) consist about 2/3 of cases of epithelial ovarian
cancer in the time of diagnosis [1-3]. Advanced epithe-
lial ovarian cancers are currently managed with laparot-
omy + hysterectomy + bilateral salpingooophorectomy +
omentectomy + resection of tumoral mass as completely
as possible and then platinum based chemotherapy.
Maximal diameter of residual tumor after surgery and
before starting chemotherapy is an important determi-
nant of prognosis, this has been shown by all studies
about advanced epithelial ovarian cancer [4-6].The defi-
nition of optimal surgery has been evolved and it is cur-
rently defined as residual tumor less than 1 cm [5].
Optimal surgery is associated with both a more favor-
able response to chemotherapy and prolonged survival
[7]. The study of GOG has shown that only if the resi-
dual tumor is optimal (less than 1 cm) the survival will
prolong[5].The success rate of primary optimal cytore-
duction for advanced epithelial ovarian cancers is highly
variable, depending upon individual and institutional
treatment philosophies and experiences. In centers with
a particular interest and experience in cytoreductive
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90% of cases [8,9].
It is not possible to do primary optimal debulking for
all patients, in these cases primary surgery not only dose
not have any benefit but also causes morbidity [10]. The
30-day mortality rate for women undergoing primary
surgery for ovarian cancer ranged from 1-3% [11].
Moreover, not performing primary surgery in all cases
result in omitting the chance of improved survival for
some patients.
Primary debulking in patients with advanced epithelial
ovarian cancer has been compared with chemotherapy
and interval debulking in different studies. Equal survi-
val has been reported in patients undergoing primary
surgery compared to patients undergoing debulking sur-
gery after taking chemotherapy by Onnes et al. [12].
They have reported that optimal debulking was achieved
in 42% of patients who treated primarily with che-
motherapy in comparison with 29% of patients who
underwent primary surgery.
In 1999, Shwartz et al. demonstrated that women who
underwent cytoreductive surgery after induction che-
motherapy had statistically improved overall survival
compared to women who did not undergo surgery[13].
One randomized prospective study demonstrated that
women undergoing interval cytoreductive surgery had
improved both overall and progression-free survival[11].
It is supposed that less invasive surgery is required for
optimal cytoreduction after neoadjuvant chemotherapy.
Ansquer et al. in their study have noticed that the mor-
bidity of cytoreductive surgery after neoadjuvant che-
motherapy is less than primary debulking [14]. It is
noticeable that by performing primary cytoreductive sur-
gery, surgical staging will be done, sensitivity to che-
motherapy will increase, risk of mutation will reduce
and general status of patient will improve. Considering
these, nowadays primary surgery is the preferred man-
agement for patients with advanced epithelial ovarian
cancer. In America 95% of patients with advanced
epithelial ovarian cancer are treated with primary sur-
gery [15].
Regarding that residual tumor is more than 1 cm in
many patients underwent primary surgiery, considering
another method in this group of patients seems neces-
sary. Although neoadjuvant chemotherapy and interval
cytoreduction sounds to be good management but its
indications have not yet determined.
A critical point in order to define indications of
neoadjuvant chemotherapy for advanced ovarian cancer
is determination of uniform selection criteria that can
consistently identify patients with surgically unresectable
disease without depriving others from potential advan-
tage associated with an optimal primary resection.
Several studies have been done for determining markers
which can reliably predict optimal resectability [16-18].
CT-Scan findings [17], serum CA-125[18], pleural effu-
sion[19] and ascites [19,20]have been assessed in differ-
ent studies in order to predict optimal debulking
preoperatively but up to now the predictive performance
of clinical parameters(e.g ascites), serum CA125 values
and imaging criteria have not demonstrated sufficient
accuracy to achieve widespread applicability[13]. Thus
further investigation concerning patient selection seems
warranted. Therefore, we planed the prospective study
for assessing the probability of predicting preoperatively
optimal cytoreduction with considering combination of
variants (abdominal and pelvic CT-scan or MRI findings
- presurgical serum CA_125 level- pleural effusion-
ascites and physical status) in patients with advanced
epithelial ovarian cancer who were admitted at gynecol-
ogy oncology ward of the Tehran Vali-e-asr hospital and
undergoing primary surgery from Jan. to June 2008.
Patients and Methods
Approval to conduct this study was obtained from
research organization of gynecologic oncology depart-
ment of Tehran University of Medical Sciences(TUMS).
Patients with stage 3 and stage 4 epithelial ovarian can-
cer underwent primary surgery between Jan. to June
2008 at gynecologic oncology ward of Vali-e-Asr hospi-
tal of TUMS were eligible for entering the study.
The possibility of predicting primary optimal cytore-
duction considering multiple variables was assessed in
this group. Variables were peritoneal carcinomatosis,
serum CA125 level, ascites, pleural effusion, physical
status and imaging findings.
All surgeries were performed by gynecologic oncolo-
gists of TUMS. Optimal cytoreduction was defined as ≤
1 cm residual disease. All imagings were reported by the
professors of radiology of TUMS. Considered imaging
parameters included: omental extention, liver involve-
ment, peritoneal involvement and suprarenal adenopa-
thy. Blood samples for measuring serum CA125 levels
were taken at the morning.
Physical statusesof patients were defined according to
physical status classification of the American society of
anesthesiology. In addition we considered optimal
and suboptimal cytoreduction. Residual tumor less than
1 cm after surgery was considered as optimal
cytoreduction.
Univariate comparisons of the percentage of patients
who underwent suboptimal cytoreduction carried out
using Fisher’s exact test for each of the potential predic-
tors. The wilcoxon rank sum test was used to compare
variables between patients with optimal versus subopti-
mal cytoreduction.
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Forty one patients from patients who were admitted at
Vali-e-Asr hospital of TUMS from Jan. to June 2008
met study inclusion criteria. Demographic and clinical
data are described in table 1. Seventy-three percent of
patients had FIGO (international federation of gynecol-
ogy and obstetrics staging system) stage 3 disease while
17% of patients had FIGO stage 4 disease. Forty-one
percent were optimally cytoreduced to ≤ 1c mr e s i d u a l
disease at the time of primary surgery.
Peritoneal carcinomatosis and suboptimal cytoreduc-
tion had statistically significant assosciation. There were
no statistically significant differences between physical
status, pleural effusion, imaging findings, CA125 serum
levels and ascites in patients with optimal cytoreduction
compared to those who underwent suboptimal
debulking.
Table 2 presents the percentage of patients who
underwent suboptimal and optimal debulking for each
of 9 considered variables. Optimal debulking was per-
formed for 44.4% of patients with physical status 1
(according to classification of American society of
anesthesiologist (A.S.A)) and 55.6% of these patients
undergoing suboptimal debulking. Patients with A.S.A
class2 suboptimally debulked in 76.9% of cases and
optimlly debulked in 23.1%.About 85% of patients have
pleural effusion were suboptimally debulked while only
14.3% of these patients were optimally debulked.
Patients who did not have pleural effusion undergoing
optimal cytoreduction in 41.2% and suboptimal cytore-
duction in 58.8%.We had only one case of bowel resec-
tion which resulted in optimal debulking. Suboptimal
debulking was performed in 84.2% of patients with peri-
toneal carcinomatosis,50% with omental extention,60%
with liver involvement,58.3% with peritoneal involve-
ment,63.3%with CA125 ≤ 400 and 59.5% with ascites ≤
1000 in comparison with optimal cytoreduction under-
going in 15.8%,50%,40%,41.7%,36.4%,45.5%of these
groups of patients respectively.
Discussion
Our current study identifies intraperitoneal carcinomato-
sis as being the only statistically significant predictor of
suboptimal cytoreduction. Table 2 demonstrates P value,
positive predictive value and negative predictive value of
each of the variables for predicting optimal and subopti-
mal debulking. There were no statistically significant
relationship between considered variables and optimal or
suboptimal cytoreduction except to intraperitoneal
carcinomatosis.
There is no statistically significant difference between
pleural effusions in individuals underwent optimal cytore-
duction compared to those with suboptimal cytoreduction.
It seems that low number of patients caused this result
because the number of patients who were suboptimally
cytoreduced is in confidence interval range of those who
were optimally cytoreduced.The number of patients in our
study is only 41. Considering small sample size of the
study, proofing these results demands larger randomized
study. We used imaging findings as predictive predictors
of suboptimal debulking according to previous studies
which had mentioned these factors have predictive value.
To date, the predictive performance of clinical para-
meters, serum CA-125 threshold values, and radiographic
imaging criteria have not demonstrated sufficient accu-
racy to achieve widespread applicability [13,21-24].
The most common criteria cited as justification for
abandoning an up-front attempt at surgical cytoreduc-
tion are ascites volume greater than 1000 ml, peritoneal
carcinomatosis, parenchymal liver disease, splenic
metastasis or omental extension to the spleen, porta
Table 1 Clinical Data and Tumor Characteristic Study
Characteristic Patients
No. %
Clinical status
1 27 65.9
2 13 31.7
Pleural effusion
Positive 7 17
Negative 34 82.9
Bowel resection
Positive 1 2.4
Negative 39 96.6
Intraperitoneal carcinomatosis
Positive 22 53.6
Negative 19 46.4
Imaging findings
Omental extension
Positive 6 14.6
Negative 34 85.4
Liver invlovement
Positive 5 12.1
Negative 36 87.9
Peritoneal involvement
Positive 12 29.2
Negative 29 70.8
Suprarenal adenopathy
Positive 0 0
Negative 41 100
CA-125
≤ 400 11 27.5
>400 29 72.5
Ascitis
≤ 1000 22 53.6
>1000 19 46.4
Mousavi et al. World Journal of Surgical Oncology 2010, 8:11
http://www.wjso.com/content/8/1/11
Page 3 of 5hepatitis disease, and bulky disease involving the dia-
phragm[8] one of the earliest studies attempting to fore-
cast the surgical outcome of patients with advanced
stage ovarian cancer assessed the predictive value of
these criteria in a series of 42 patients[15].In this senti-
nel study, Nelson et al reported a positive predictive
value for a suboptimal surgical result of 67%.Not to be
overlooked, it is the fact that one out of every three
patients thought to have unresectable tumor would have
been left with optimal residual disease if offered primary
surgery. More recently, Axtell et al. [25] reported data
that highlight the difficulty in defining universally
applicable selection criteria that reliably predict surgical
outcome across institutions and surgeons.
One of the principle difficulties in development of any
reliable predictive model of surgical outcome for patients
with advanced ovarian cancer is the challenge of factors
in the significant impact of each institute surgeons’
philosophy, effort and ability to utilize advanced surgical
techniques to achieve maximal cytoreduction, in order to
omit this factor, in this study all surgeries were per-
formed by gynecologic oncology professors of TUMS.
In summary, identification of risk factors for subopti-
mal cytoreduction in small populations such as ours is
not reproducible in alternate populations. Until prospec-
tive randomized trials have demonstrated that neoadju-
vant chemotherapy followed by interval cytoreduction is
equivalent in terms of survival outcomes to primary
optimal cytoreduction followed by chemotherapy,
extreme caution should be used when applying preo-
perative predictors to decide between primary surgical
exploration and neoadjuvant chemotherapy in the medi-
cally fit patient. Only the patient who is most unlikely
to undergo optimal cytoreduction should be offered
neoadjuvant chemotherapy, unless her medical condition
renders her unsuitable for primary surgery.
Table 2 Univariate Analysis of Predictors of Suboptimal Cytoreduction
patients
Optimal Cytoreduction Suboptimal Cytoreduction
Predictor No. percent No. percent P
Clinical status
1 12 44.4 15 55.6 1.91
2 3 23.1 10 76.9
Pleural effusion
Positive 1 14.3 6 85.7 .179
Negative 14 41.2 20 58.8
Peritoneal carcinomatosis
Positive 3 15.8 16 84.2 .01
Negative 12 54.5 10 45.5
Omental extension
Positive 3 50 3 50 .460
Negative 12 34.3 23 65.7
Liver involvement
Positive 2 40 3 60 .866
Negative 13 36.1 23 63.9
Peritoneal involvement
Positive 5 41.7 7 58.3 .664
Negative 10 34.5 19 65.5
Adenopathy
Positive 0 0 0 0
Negative 15 36.6 26 63.4
CA-125
≤ 400 4 36.4 7 63.6 .911
>400 10 34.5 19 65.5
Ascitis
≤ 1000 10 45.5 12 54.5 .205
>1000 5 26.3 14 73.7
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